PMID- 30651063
OWN - NLM
STAT- MEDLINE
DCOM- 20191212
LR  - 20201209
IS  - 1471-2261 (Electronic)
IS  - 1471-2261 (Linking)
VI  - 19
IP  - 1
DP  - 2019 Jan 16
TI  - Morbidity and mortality in a population of patients affected by heart failure and 
      chronic obstructive pulmonary disease: an observational study.
PG  - 20
LID - 10.1186/s12872-018-0986-y [doi]
LID - 20
AB  - BACKGROUND: Chronic obstructive pulmonary disease (COPD) and heart failure (HF) 
      often coexist. Moreover, elderly patients suffering from HF have a higher 
      incidence of COPD, which further complicates their clinical condition. 
      Indacaterol/glycopirronium has shown benefits in the treatment of COPD, with few 
      cardiologic adverse effects. We evaluated the safety and efficacy of this therapy 
      in patients with history of HF. METHODS: We enrolled 56 patients with a history 
      of HF (New York Heart Association [NYHA] classes II and III) and stable COPD. We 
      evaluated blood samples, clinical assessment, echocardiograms and basal 
      spirometry at baseline and after 6 months of therapy with 
      indacaterol/glycopirronium. In addition, the number of re-hospitalizations during 
      the treatment period was evaluated. RESULTS: The treatment was well tolerated. 
      Brain natriuretic peptide (BNP) levels were significantly reduced compared with 
      baseline (p < 0.001) after 6 months of treatment, and a higher percentage of 
      patients improved their clinical status compared with baseline (p < 0.001). Minor 
      changes were noted in the hemodynamic and metabolic parameters. Significant 
      improvements in the echocardiographic parameters were noted in HF with reduced 
      ejection fraction (HFrEF) patients. All respiratory parameters (forced expiratory 
      volume in 1 s [FEV1], FEV1/forced vital capacity [FVC] ratio and COPD Assessment 
      Test [CAT] scores) improved significantly (p < 0.001). No hospitalizations owing 
      to HF or COPD exacerbation occurred. One patient died of respiratory failure. 
      CONCLUSION: Indacaterol/glycopirronium was well-tolerated and effective in the 
      treatment of COPD in this cohort of patients with a history of HF. Further 
      studies are needed to clarify whether this compound can have a direct role in 
      improving overall cardiovascular function.
FAU - Cosentino, Eugenio Roberto
AU  - Cosentino ER
AUID- ORCID: 0000-0002-2979-783X
AD  - Cardio-Thoracic-Vascular Department, Policlinico S. Orsola-Malpighi, Universita 
      di Bologna, Via Albertoni 15, 40138, Bologna, Italy. eugecose@yahoo.it.
FAU - Landolfo, Matteo
AU  - Landolfo M
AD  - Cardio-Thoracic-Vascular Department, Policlinico S. Orsola-Malpighi, Universita 
      di Bologna, Via Albertoni 15, 40138, Bologna, Italy.
FAU - Bentivenga, Crescenzio
AU  - Bentivenga C
AD  - Cardio-Thoracic-Vascular Department, Policlinico S. Orsola-Malpighi, Universita 
      di Bologna, Via Albertoni 15, 40138, Bologna, Italy.
FAU - Spinardi, Luca
AU  - Spinardi L
AD  - Cardio-Thoracic-Vascular Department, Policlinico S. Orsola-Malpighi, Universita 
      di Bologna, Via Albertoni 15, 40138, Bologna, Italy.
FAU - Esposti, Daniela Degli
AU  - Esposti DD
AD  - Cardio-Thoracic-Vascular Department, Policlinico S. Orsola-Malpighi, Universita 
      di Bologna, Via Albertoni 15, 40138, Bologna, Italy.
FAU - Cicero, Arrigo Francesco
AU  - Cicero AF
AD  - Cardio-Thoracic-Vascular Department, Policlinico S. Orsola-Malpighi, Universita 
      di Bologna, Via Albertoni 15, 40138, Bologna, Italy.
FAU - Miceli, Rinaldo
AU  - Miceli R
AD  - Cardio-Thoracic-Vascular Department, Policlinico S. Orsola-Malpighi, Universita 
      di Bologna, Via Albertoni 15, 40138, Bologna, Italy.
FAU - Bui, Virna
AU  - Bui V
AD  - Cardio-Thoracic-Vascular Department, Policlinico S. Orsola-Malpighi, Universita 
      di Bologna, Via Albertoni 15, 40138, Bologna, Italy.
FAU - Berardi, Emanuela
AU  - Berardi E
AD  - Cardiology Department, Hospital S. Valentino, Treviso, Montebelluna, Italy.
FAU - Borghi, Claudio
AU  - Borghi C
AD  - Cardio-Thoracic-Vascular Department, Policlinico S. Orsola-Malpighi, Universita 
      di Bologna, Via Albertoni 15, 40138, Bologna, Italy.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20190116
PL  - England
TA  - BMC Cardiovasc Disord
JT  - BMC cardiovascular disorders
JID - 100968539
RN  - 0 (Adrenergic beta-2 Receptor Agonists)
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Indans)
RN  - 0 (Muscarinic Antagonists)
RN  - 0 (Quinolones)
RN  - 0 (indacaterol-glycopyrronium combination)
RN  - V92SO9WP2I (Glycopyrrolate)
SB  - IM
MH  - Adrenergic beta-2 Receptor Agonists/adverse effects/*therapeutic use
MH  - Aged
MH  - Aged, 80 and over
MH  - Bronchodilator Agents/adverse effects/*therapeutic use
MH  - Comorbidity
MH  - Drug Combinations
MH  - Female
MH  - Glycopyrrolate/adverse effects/*therapeutic use
MH  - Heart Failure/diagnostic imaging/mortality/*physiopathology
MH  - Heart Ventricles/diagnostic imaging/*drug effects/physiopathology
MH  - Humans
MH  - Indans/adverse effects/*therapeutic use
MH  - Italy/epidemiology
MH  - Lung/*drug effects/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Muscarinic Antagonists/adverse effects/*therapeutic use
MH  - Patient Readmission
MH  - Pulmonary Disease, Chronic Obstructive/diagnosis/*drug 
      therapy/mortality/physiopathology
MH  - Quinolones/adverse effects/*therapeutic use
MH  - Recovery of Function
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC6335816
OTO - NOTNLM
OT  - Chronic obstructive pulmonary disease
OT  - Elderly
OT  - Heart failure
OT  - Indacaterol/glycopirronium
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Yes. Informed, written consent was 
      obtained from all participants. The study was evaluated by the ethical board of 
      the S. Orsola-Malpighi University Hospital. CONSENT FOR PUBLICATION: Yes 
      COMPETING INTERESTS: The authors declare that they have no competing interests. 
      PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional 
      claims in published maps and institutional affiliations.
EDAT- 2019/01/18 06:00
MHDA- 2019/12/18 06:00
PMCR- 2019/01/16
CRDT- 2019/01/18 06:00
PHST- 2018/08/27 00:00 [received]
PHST- 2018/12/20 00:00 [accepted]
PHST- 2019/01/18 06:00 [entrez]
PHST- 2019/01/18 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
PHST- 2019/01/16 00:00 [pmc-release]
AID - 10.1186/s12872-018-0986-y [pii]
AID - 986 [pii]
AID - 10.1186/s12872-018-0986-y [doi]
PST - epublish
SO  - BMC Cardiovasc Disord. 2019 Jan 16;19(1):20. doi: 10.1186/s12872-018-0986-y.